Innovative Approach to Sustain the Release of the Drug from Conventional Dosage Form Nifedipine Sustained Release Tablet
Prashant
Khemariya1*, Kaushal Dubey2, Richa Khemariya3
2SRK Pharmaceuticals,
India
3Swami Vivekananda University, India
Citation: Khemariya P, Dubey K, Khemariya R (2017) Innovative Approach to Sustain the Release of the Drug from Conventional Dosage Form Nifedipine Sustained Release Tablet. J Nanomed Nanosci: JNAN-115. DOI: 10.29011/JNAN-115. 100015
1.
Abstract
1.
Introduction
Bio-pharmaceutics Classification System likewise named as BCS, it describes drug molecules in four classes, based on their aqueous solubility and permeability. Classification of system was developed by Amidon, et al. [1].
1)
Class
I-High Permeability, High Solubility, Class II-High Permeability, Low
Solubility
2)
Class
III-Low Permeability, High Solubility and Class IV-Low Permeability, Low
Solubility.
Materials- we used Diluents-MCC 101, MCC102, Corn Starch, Soluble Starch, Lactose Monohydrate, Glidant -Aerosil, Lubricant-Magnesium stearate, Stearic acid, Binder-PVPK-25 and PVPK-30. All other chemical reagents used were of pharmaceutical grade. All aqueous solutions were prepared exclusively in distilled water and non-aqueous solution in IPA and MDC.
2.1 Preparation of SRmixK
We
found that granules with soluble starch, Mannitol, Lactose and PVPK-25 were
very soft while Corn Starch, PVPK-30, Mannitol and
2.3. Evaluation of Granules
Angle of Repose: Angle of repose is defined as the maximum angle possible between the surface of the pile of powder and horizontal plane. The angle of repose of the granules was determined by fixed funnel method to assess the flow property of the granules. The diameter of the granules cone (d) and the height (h) of the pile were noted. From the diameter, radius (r) was calculated. The angle of repose (θ) Was calculated using the following formula [8,9].
Ɵ =(tan)^(-1)*(h/r)
Tapped Density (TD): An accurately weighed 25g of granules transferred in a 100mL graduated cylinder. Then mechanically tap the cylinder containing the sample by raising the cylinder and allowing it to drop under its own weight using mechanically TD tester that provides a fixed drop of 14±2mm at a nominal rate of 300 drops per min. Tap the cylinder for 500 times initially and measure the tapped volume (V1) to the nearest graduated units, repeat the tapping an additional 750 times and measure the tap volume (Vf) to the nearest graduated units. If the difference between the two volumes is less than 2% of final the volume (Vf). Calculate the tapped BD by the following formula [9-11].
TD = Mass of the granules (W)/ Tapped volume of the granules (Vf).
Carr’s index (%) = [(TD-BD) ×100] / TD.
Hausner’s Ratio: Hausner’s ratio is a number that is correlated to the flowability of a powder.
2.4.2. Uniformity of Weight: Weight variation was determined by weighing 20 tablets individually, the average weight was calculated and the percent variation of each tablet from the average weight of tablet was calculated [10,11].
2.4.3. Friability: The friability of the tablets was determined using 10 tablets from each formulation, with a friability tester (Erweka TAR-20) at a speed of 25rpm for 4min. The tablets were weighed before and after the friability test, and friability was determined as percent weight change [10,11].
2.4.4. Hardness: Hardness was determined by taking six tablets from each formulation using a digital tablet hardness tester (TBH 210 Erweka) and the average of pressure (N) applied for crushing the tablet was determined
2.4.5. Drug content (Assay): Ten tablets were weighed from each formulation, powdered and equivalent to 20mg of nifedipine were weighed and dissolved in sufficient quantity of methanol and make up to 100ml with methanol. The solutions were suitably diluted with buffer solution pH 1.2 and the content of nifedipine was estimated spectrophotometrically at 238nm using pH 1.2 as a blank.
2 2. 5 In Vitro Drug Release Study
In vitro release rate studies were carried out using dissolution apparatus type 2 (USP XXVIII) in 900ml of sodium phosphate buffer (pH 7.4) with 1% w/v sodium lauryl sulfate maintained at 37±0.5°C. The stirring speed was set at 50 rpm. At predetermined time intervals, a 5-ml sample was withdrawn and replaced with fresh dissolution media up to 12hrs. After appropriate dilutions, the samples were analyzed by the UV spectrophotometric method at 238nm. Cumulative percent of drug released was calculated and the mean of three tablets each from three different batches was used in data analysis.
2.6 Characterization of Release Kinetics
To
study the release kinetics of Nifedipine from the tablets, the release data
were fitted to the following equations:
Zero
order equation
Q.t = k0.t
Where Q is the percentage of drug released at time t and k0 is the release rate constant;
First
order equation
ln
(100-Qt) = ln100-k1.t
Where k1is the release rate constant;
Higuchi’s
equation
Q.t = kH.t1/2
Where kH is the Higuchi release rate constant;
Furthermore, in order to better characterize the drug release mechanisms for the polymeric systems studied, Korsmeyer- Peppas semi-empirical model was applied: Qt/Q∞= kKP.tn
Where Qt/Q∞ is the fraction of drug released at time t, kKP a constant compromising the structural and geometric characteristics of the device, and n, the release exponent, which is indicative of the mechanism of drug release.
For the
case of cylindrical geometries such as tablets, n=0.45 corresponds to a Fickian
diffusion release (Case I), 0.45
3. Results and Discussion
3.1. Evaluation of SRmixK and Nifedipine Granules
3.2 Physical Characterization
of the Tablets
All the
trial formulations were prepared as per the formula summarized in (Table 1). The prepared matrix tablets were evaluated
for various physical properties as indicated in (Table
3).
All the
batches were produced under similar conditions to avoid processing variables.
Tablets of different formulations were subjected to various evaluation tests,
such as thickness, uniformity of weight, drug content, hardness, friability and
in vitro
dissolution. As summarized in (Table 4).
All formulations showed uniform thickness. The weight variations of the tablet were between 0.38 and 1.67% which complying with pharmacopoeia specification. The tablets also passed the friability test while the friability ranged <1%. All the results are showing that the sustained release pattern can be achieved by numerous new generation excipients but our aim was to develop an excipient with SR release capacity. We found that SRmixK is having better sustained release capability as compare to Eudragite RS, LS or HPMC.
4. Stability Studies
Stability
Study of a drug, Excipients or finished product has been defined as the ability
in a specific packing, to remain within its physical, chemical, therapeutic and
toxicological specifications. The purpose of stability testing is to provide
evidence on how the quality of a drug substance or drug product varies with
time (Table 5).
Under the influence of a variety of environmental factors such as temperature, humidity a light and enables recommended storage conditions, retest periods and shelf lives to be established. ICH Q1R (2) described all the details of Stability Study [5].
In the present work stability studies were carried out at 400C / 75 % RH for a specific time up to 6 months for the selected formulations and SRmixK
4.1. Drug Release Kinetics
The in vitro release profile of drug from formulations with SRmixK could be best expressed by Higuchi’s equation, as the plot showed high linearity (r2=0.991) indicating that the release is principally controlled by diffusion. The Higuchi model is usually considered to be applicable up to about 75-83% of the drug released (Table 6).
4.2. In Vitro Drug Release Studies
In the present research study, various retarding hydrophilic and hydrophobic polymers were used to control the release of Nifedipine from matrix tablets. To consider the effect of polymer type and percentage on drug release profile, different formulations containing various percentages of SRmixK HPMC, EC, Eudragit RSpo and RLpo and their combinations were prepared [12-16].
5. Conclusion
Sustained
release formulation is the drug delivery system that is designed to achieve a
prolonged therapeutic effect by continuously releasing medication over an
extended period of time after administration of single dose. Sustained release
dosage form of Nifedipine using newly prepared material SRmixK and Drug release
tested for 12 hours showed maximum for Batch F5 in an average 97.5%. Analysis
of parameters for diameter, thickness, average weight, hardness and uniformity
of weight under the limit of the Pharmaceutical for its effective formulation
purpose. In (Figure 1).
Figure 1:
Comparative drug release (mean±SD) profiles from
compressed tablet by using different materials and newly prepared SRmixK. clearly
representing that prepared mix SRmixK drug release profile better and constant
as compare to other materials.
Sr. |
Starch |
PG Starch |
PVPK-25 |
PVPK-30 |
Mannitol |
Lactose |
MCC 101 |
MCC 102 |
Total |
S1 |
19.50 |
25.60 |
2.50 |
- |
52.40 |
- |
- |
- |
100 |
S2 |
- |
36.50 |
12.48 |
3.50 |
21.78 |
25.74 |
- |
- |
100 |
S3 |
- |
- |
1.50 |
3.50 |
65.12 |
21.50 |
8.38 |
- |
100 |
S4 |
- |
54.00 |
2.20 |
- |
- |
- |
43.80 |
- |
100 |
S5 |
97.20 |
2.80 |
- |
- |
- |
- |
- |
- |
100 |
S6 |
23.00 |
18.00 |
2.50 |
- |
- |
- |
- |
56.50 |
100 |
S7 |
36.00 |
- |
- |
2.50 |
30.00 |
- |
- |
31.50 |
100 |
S8 |
25.00 |
25.00 |
3.00 |
- |
12.00 |
9.00 |
26.00 |
- |
100 |
S9 |
- |
- |
- |
7.00 |
35.00 |
14.00 |
- |
44.00 |
100 |
All above said quantities are in gm Table representing different formulations (S1-S9) with different concentration of excipients. Solvent used to get granular form of SRmixK-Distilled water, IPA, and IPA: MDC (70:30). |
Table 1: Formulation of SRmixK.
Film Coating on F5,6,7,8 and F12 Formulation. |
||
Sr. No. |
Material |
per tab |
1 |
Film Coating Material |
3mg |
2 |
IPA |
8mg |
3 |
MDC |
8mg |
The above table representing film coating of tablets formulated with SRmixK.
|
Table 2: Film Coating Parameters.
Sr. No. |
Hardness (k/cm) |
Thickness (mm) |
Friability (%) |
Weight variation (% |
Disintegration time |
F1 |
4.5 |
2.62 |
0.26 |
0.56 |
1.1 |
F2 |
4.5 |
2.59 |
0.3 |
0.99 |
1.2 |
F3 |
5.3 |
2.63 |
0.19 |
1.25 |
1.6 |
F4 |
5.2 |
2.67 |
0.29 |
1.02 |
2.1 |
F5 |
5 |
2.66 |
0.36 |
1.08 |
3.3 |
F6 |
4.5 |
2.71 |
0.21 |
1.1 |
4.2 |
F7 |
5 |
2.73 |
0.26 |
1.9 |
3.8 |
F8 |
4.5 |
2.64 |
0.41 |
1.21 |
5.2 |
F9 |
5 |
2.66 |
0.27 |
0.48 |
1.6 |
F10 |
5.5 |
2.75 |
0.31 |
0.78 |
2.6 |
F11 |
5.5 |
2.66 |
0.36 |
0.98 |
6.5 |
F12 |
5.5 |
2.75 |
0.21 |
1.98 |
2.9 |
F13 |
6 |
2.9 |
0.38 |
1.24 |
4.6 |
Table representing post compression data of Tablets with different formulations. Disintegration time is in minute. All formulations had less than 1% of friability. |
Table 3: Physical Parameters of compressed tablets.
Sr. |
Nifedipine |
Lactose |
MCC101 |
MCC102 |
Starch |
Srmixk |
PVPK30 |
Eudragite RS |
Eudragite LS |
HPMC |
Ethyle Cellulose |
Mg Stearate |
Total |
F1 |
20 |
33 |
27 |
- |
- |
- |
3 |
15 |
- |
- |
- |
2 |
100 |
F2 |
20 |
18 |
21.2 |
20 |
- |
- |
4 |
- |
15 |
- |
- |
1.8 |
100 |
F3 |
20 |
- |
32 |
25 |
- |
2.5 |
18 |
- |
- |
- |
2.5 |
100 |
|
F4 |
20 |
- |
- |
45 |
18.2 |
- |
- |
- |
- |
15 |
- |
1.8 |
100 |
F5 |
20 |
5 |
- |
66 |
- |
2 |
- |
- |
- |
- |
- |
2 |
95 |
F6 |
20 |
18 |
- |
43.5 |
- |
12 |
- |
- |
- |
- |
- |
1.5 |
95 |
F7 |
20 |
- |
61.5 |
- |
- |
12 |
- |
- |
- |
- |
- |
1.5 |
95 |
F8 |
20 |
- |
32.3 |
33 |
- |
8 |
- |
- |
- |
- |
- |
1.7 |
95 |
F9 |
20 |
45 |
- |
- |
- |
- |
- |
- |
- |
- |
28.5 |
1.5 |
95 |
F10 |
20 |
- |
29 |
19.5 |
5 |
- |
- |
- |
- |
- |
20 |
1.5 |
95 |
F11 |
20 |
66 |
- |
- |
- |
- |
2 |
- |
15 |
- |
- |
2 |
105 |
F12 |
20 |
- |
- |
37 |
28 |
9 |
- |
- |
- |
- |
10 |
1 |
105 |
F13 |
20 |
12 |
18 |
- |
28 |
- |
2 |
- |
24.5 |
0.5 |
105 |
||
All above said quantities are in gm/ tablet. Table representing different formulations (F1-F13) of tablets with different concentration of excipients. |
Table 4: Formulation of Sustained Release Tablet of Nifedipine.
Terms of Study |
Storage condition |
Minimum time period for study |
||
Accelerated |
40°C ± 2°C |
75% RH ± 5% RH |
6months |
|
Long-term* |
25°C ± 2°C
30°C ± 2°C |
60% RH ± 5% RH
65% RH ± 5% RH |
12months |
|
Intermediate** |
30°C ± 2°C |
65% RH ± 5% RH |
6months |
|
Conditions are depending of climatic zones. * It is up to the applicant to decide whether long-term stability sturdies are performed at 25°C±2°C/60% RH ± 5% RH or 30°C ± 2°C/65% RH ± 5% RH. ** If 30°C ± 2°C/65% RH ± 5% RH is the long-term condition, there is no intermediate condition. |
Table 5: Stability study conditions and duration as per ICH guidelines.
In-vitro drug release from different formulations |
|||||||||||||
Time (h) |
F1 |
F2 |
F3 |
F4 |
F5 |
F6 |
F7 |
F8 |
F9 |
F10 |
F11 |
F12 |
F13 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
7.2 |
7.6 |
6.5 |
7.2 |
8.1 |
6.5 |
6.9 |
7.2 |
7 |
7.1 |
6.8 |
6.5 |
6.1 |
2 |
12.1 |
11.5 |
12.8 |
13.5 |
14.7 |
12.6 |
14.5 |
12.9 |
11.8 |
13.1 |
12.9 |
11.98 |
13.5 |
4 |
25.9 |
26.8 |
31.2 |
29.2 |
35.1 |
30.5 |
31.2 |
29.8 |
28.9 |
29.7 |
29.9 |
31.8 |
31.3 |
6 |
40.8 |
39.8 |
39 |
39 |
47.9 |
42.2 |
46.8 |
42.1 |
39.4 |
41 |
43.2 |
40.8 |
39.7 |
8 |
59.9 |
53.5 |
54.1 |
57.7 |
67.7 |
65.2 |
68.2 |
60.1 |
57.8 |
52.5 |
58.3 |
54 |
64 |
10 |
65 |
60.1 |
62 |
72.5 |
78.1 |
73.5 |
75.9 |
75.2 |
69.9 |
68.2 |
71 |
70.9 |
73.3 |
12 |
71 |
69.9 |
71.2 |
75.2 |
97.5 |
78.2 |
83.2 |
85.8 |
87.6 |
86.5 |
84.6 |
85.2 |
89.9 |
Table representing drug releases from compressed SR tablet, with time interval. |
Table 6: In-vitro drug release from different formulations.
5.
ICH Guidelines. Q1R2/ general case.
7.
The Statistics Portal. Statistics and Studies from
more than 18,000 Sources.
9.
PDR
(Physicians’ Desk Reference) (2000) 54th ed. Medical Economics Company Inc,
Montvale NJ 331: 2363.
15. Colombo P (1993) Swelling-controlled release in hydrogel
matrices for oral route. Adv Drug Deliv Rev 11: 37-57.